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ABSTRACT 
The effect of copper(II) complexes on glucose metabolism was 
studied in normal and streptozotocin-induced diabetic rats. The cop- 
per(II) complexes used were bis(acetato)tetrakis(imidazole) c pper 
(II), [Cu(OAc)2(Im)4], bis(acetato)bis(2-methylimidazole) copper(II), 
[Cu(OAc)2(2mIm)2], bis(acetato)bis(1,2-dimethylimidazole) copper(II), 
[Cu(OAc)2(1,2dmIm)2], and bis(acetato)bis(p-acetato)tetrakis(N-me- 
thylimidazole) copper(II) hexaaquo, [Cu2(OAc)4-(NmIm)4]-6H20. 
Intramuscular administration of various doses of Cu(OAc)2(Im)4 
ranging from 10 to 100 mg/kg body mass to overnight fasted rats 
decreased blood glucose levels in a dose-dependent manner. Maxi- 
mum hypoglycemic effect was observed 3 h after administration a d 
lasted for at least 6 h. Treatment with 100 mg/kg body mass of 
Cu(OAc)2(Im)4 caused hypoglycemic shock, which was irreversible 
and even lethal. Blood insulin levels were reduced sharply during 
this hypoglycemic shock. Similar changes in blood glucose level were 
achieved using Cu(OAc)2(2mIm)2. 
The same pattern of hypoglycemia, lthough less pronounced, 
was observed for Cu2(OAc)4(NmIm)4-6H20 and Cu (OAc)2 (1,2dmlm)2. 
Binary copper(II) acetate complex, the ligand imidazole, and the inor- 
ganic form of copper, such as copper(II) chloride, had no significant 
effect on blood glucose level. These results indicate that the hypo- 
glycemic activity of these complexes varies with the imidazole ligand 
and structure of the complex. 
*Author to whom all correspondence and reprint requests hould be addressed. 
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Intramuscular dministration of Cu(OAc)2(Im)4 to diabetic rats 
caused a reduction in blood glucose levels and improved their toler- 
ance for glucose. 
Index Entries: Copper(II) complexes; streptozotocin-induced 
diabetes; hypoglycemia; glucose tolerance test. 
INTRODUCTION 
Over the last 20 years, copper complexes were found to possess anti- 
inflammatory (1-3), antiulcer (4), anticonvulsant (5,6), and antidiabetic 
activities (7). 
The antidiabetic activity of copper complexes was first reported 
using two copper complexes, copper(II)2 (3,5-diisopropyl-salicylate)4 and
copper(II)2 (salicylate)4 (6,8). They improved glucose tolerance in strep- 
tozotocin-treated rats, whereas their parent ligands, salicylic acid and 3,5- 
diisopropylsalicylic acid, had no antidiabetic activity. 
Inorganic copper has some antidiabetic properties (7). It stimulates 
glucose incorporation into glycogen in diaphragm muscle (9) and epi- 
didymal adipose tissue of normal and streptozotocin-diabetic rats (10). 
Cohen and Miller have reported that inorganic opper stimulates insulin 
release from the perfused rat pancreas (11). 
The present study was undertaken to investigate the hypoglycemic 
effect of four copper(II) acetate imidazole complexes: 
1. Cu(OAc)2(Im)4; 
2. Cu2(OAc)4(NmIm)4- 6H20; 
3. Cu(OAc)2(1,2dmIm)2; and 
4. Cu(OAc)2(2mIm)2. 
(OAc = acetate anion, Im = imidazole, NmIm = N-methylimidazol, 
1,2dmIm = 1,2dimethylimidazol, and 2mIm = 2-methyl imidazole). The 
molecular structures of the complexes under investigation have been pre- 
viously characterized (12-14) and are depicted in Fig. 1. 
MATERIALS AND METHODS 
Reagents and Materials 
Copper(II) chloride, copper(II) acetate monohydrate, imidazole, and 
its methyl derivatives were purchased from Aldrich (Milwaukee, WI). 
Copper(II) acetate complexes with imidazole or methyl imidazoles were 
synthesized and characterized as previously described (12-14). Dextro- 
stix strips were purchased from Ames, (Miles, Paris), and streptozotocin 
(STZ) was obtained from Sigma (St. Louis, MO). 
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Fig. 1. The molecular structures of copper(II) complexes, Cu(OAc)2(Im)4 
(A), Cu2(OAc)4(NmIm)4 9 6H20(B), Cu(OAc)2(1,2dmIm)2(C), andCu(OAc)2(2mIm)2 
(D) (adapted from refs. (12-14)). 
Animals and Administration of Drugs 
Male 150-250 g Sprague Dawley rats were fasted for 18 h, but 
allowed water ad libitum before use in these experiments. Groups of 
6-12 animals were injected intramuscularly (ira) or intrapertoneally (ip) 
with 100 mg/kg body mass of the following compounds: Cu(OAc)2(Im)4, 
Cu(OAc)2(2mlm)2, Cu(OAc)2(1,2dmlm)2, and Cu2(OAc)4(Nmlm)4 
6H20, or vehide containing imidazole, copper(II)2 (acetate)4 or copper(II) 
chloride. In other experiments, doses of 10, 20, 40, 50, 60, or 100 mg/kg 
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Cu(OAc)2(Im)4 were injected intramuscularly (ira) to overnight fasted 
animals to study dose response. 
Experimental diabetes was induced by subcutaneous (SC) injection of 
35 mg streptozotocin/kg body mass dissolved in 100 mM sodium acetate 
buffer, pH 5.2. Diabetes was assessed by monitoring blood glucose level 
and by ip glucose tolerance test. Animals were considered as diabetic 3 
wk after injection of STZ, when blood glucose levels were between 300 
and 400 mg/dL. Cu(OAc)2(Im)4 50 mg/kg was administered im to 18-h 
fasted diabetic animals 2 h before ip injection of 0.5 g glucose/kg body 
mass as a 25% solution with water. Blood samples were taken from the 
tail tip after 15, 30, 60, 90, and 120 rain following glucose injection. 
In other experiments, normal fasted rats were injected orally with 
different doses of Cu(OAc)2(Im)4 ranging from 50 to 1000 mg/kg, and in 
other groups, iv injection of smaller doses of 5-10 mg/kg of the same 
compounds were used. 
The effect of Cu(OAc)2(Im)4 on blood insulin was determined after 
injecting 50 mg/kg ira, while control animals were injected with an 
equal volume of saline. Three hours after injection, blood was collected 
from the abdominal artery, and insulin was determined using the Amer- 
sham (UK) Insulin Kit. Blood glucose was measured using a glucometer 
and Dextrostix strips (15). Student's t-test was used for all statistical 
analyses. 
RESULTS 
Hypoglycemic Effect of Cu(OAc)2 (Ira)4 
Table 1 and Fig. 2 show that intramuscular administration f various 
concentrations of Cu(OAc)2(Im)4 ranging from 10 to 100 mg/kg body 
mass to overnight fasted rats reduced blood glucose level in a dose- 
related fashion. The maximum hypoglycemic effect was observed 3-5 h 
after injection of Cu(OAc)2(Im)4. A 15% reduction was observed with 20 
mg/kg, 34% with 40 mg/kg, 48% with 50 mg/kg, and 51% with 60 
mg/kg 5 h after treatment. The ypoglycernic effects were not observable 
at 24 h after treatment. The dose of 10 mg/kg produced only a weak 
hypoglycemic effect, which was not significant (P > 0.05), and the high 
dose of 100 mg/kg produced irreversible hypoglycemic shock, which 
was lethal. 
Oral administration of up to 1000 mg/kg produced no hypo- 
glycemic activity, whereas iv administration of 10 mg/kg was lethal 
within 5-10 min without showing any signs of hypoglycemia. 
Intramuscular injection of 50 mg Cu(OAc)2(Im)4/kg significantly 
reduced blood insulin concentration from a normal value of 40.10 +_ 7.74 
(5) ~tU/mL to 8.60 + 3.22 (5) ~tU/mL (P < 0.025) (Table 2). 
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Blood glucose Hypoglycemic 
Dosage mg% effect P < 
0 90.24 _+ 2.78 (6) - -  - -  
10 mg/kg 84.00 _+ 2.71 (6) 7% NS 
20 mg/kg 76.47 _+ 3.06 (7) 15% 0.05 
40 mg/kg 59.78 _+ 3.21 (7) 34% 0.0025 
50 mg/kg 47.19 + 2.83 (6) 48% P < 0.0005 
60 mg/kg 44.19 _+ 2.46 (6) 51% P < 0.0005 
100 mg/kg 17.28 + 2.55 (12) 81% P < 0.0005 
Blood glucose measured in the tail tip 300 min after treatment with different doses 
of Cu(OAc)2(Im)4. The data are normalized to the initial value of 100%, and all subse- 
quent values expressed r lative to the initial level. Hypoglycemic effect is the percentage 
reduction in blood glucose compared to the saline-treated animals. The number of ani- 
mals indicated in parenthesis. 
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Fig. 2. Hypoglycemic effect of Cu(OAc)2(Im)4. Rats were injected im with 
various doses of Cu(OAc)2(Ira)4. 10 mg/kg (@ A~.vj, 20 mg/kg (0- - - -0); 
40 mg/kg (O O); 50 mg/kg (~. -~); 60 mg/kg (O-- - - --O); or 
100 mg/kg (0- . . . . .  -0). Values are the mean for 6-12 rats/group. Error bars have 
been omitted for clari~. 
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Table 2 
Changes in Blood Insulin Content 
following im Injection of Cu(OAc)2(Irn)4 50 mg/kg 
Blood insulin content (~tU/mL) 







+ 7.74 (5)a 8.60 + 3.22 (5) 
$ 78% P < 0.025b 
Normal values 25-80 ~tU/mL. The animals were killed 
3 h after injection of CAI (50 mg/kg ira). Blood was col- 
lected from the abdominal artery for the determination of 
insulin levels. 
aThe average _+ SEM of the five animals tested. 
bpercent reduction i  insulin values. 
Hypoglycemic Activity for Various 
Copper Complexes 
The hypoglycemic effect of copper complexes varies with the com- 
plex structure (Table 3). Cu(OAc)2(Im)4, 100 mg/kg  ira, caused 77% 
reduction in blood glucose level 4 h after treatment compared to saline- 
treated animals (P < 0.0005). The same treatment with Cu(OAc)2(2mIm)2 
caused a 76% decrease in blood glucose level, whereas Cu2(OAc)4- 
(Nmlm)4 9 6H20 and Cu(OAc)2(1,2dmIm)2 produced reductions of 43 
and 37%, respectively. An inorganic form of copper, CuC12, was less 
active and reduced blood glucose only by 15%, which was nonsignifi- 
cant. Binary copper(II) acetate complex and the ligand imidazole each 
administrated (100 mg/kg)  caused a nonsignificant reduction of 15-16%. 
All changes exerted by these copper compounds persisted for 3--6 h after 
administration. Similar results were achieved with ip injection. 
The Effect of Cu(OAc)2(lm)4 on Glucose 
Tolerance in Diabetic An imals  
Intraperitoneal dministration of 500 mg glucose/kg to fasted dia- 
betic animals produced a significant rise in blood glucose, which reached 
a maximum level after 30 min (P < 0.001). Blood glucose levels remained 
higher than baseline values for about 2 h after glucose administration. 
The effect of Cu(OAc)2(Im)4 on glucose tolerance in diabetic animals is 
shown in Fig. 3. 
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Hypoglycemic Effect of Different Copper(II) Compounds 
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70.40 _+ 4.35 (5) 
60.52 _+ 3.90 (5) 15% 
60.07 _+ 5.15 (5) 15% 
59.03 + 4.83 (5) 16% 
44.50 _+ 2.82 (6) a 37% 
40.05 + 4.29 (6)b 43% 
16.62 _+ 2.29 (6) c 76% 
16.28 _+ 2.90 (12) c 77% 
Blood glucose was measured in the tail tip 4 h after treatment with copper com- 
pounds (100 mg/kg im). Hypoglycemic effect is the percentage reduction in blood glu- 
cose compared to the saline-treated animals. 
NS = nonsignificant. 
ap < 0.01. 
bp < 0.02. 







Minutes After Glucose Injection, 
Fig. 3. Effect of Cu(OAc)2(Im)4 on the glucose tolerance test of diabetic 
rats, which were injected im either with saline (@ e) or Cu(OAc)2(Im)4 
(~ ~t) for 2 h before glucose tolerance test. Each point represents the 
mean of the glucose values of eight rats. 
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Pretreatment with Cu(OAc)2(Im)4, 50 mg/kg ira, 120 rain before 
injection of glucose reduced the maximum glucose value by 55%, as 
compared to saline-treated control animals (P < 0.05). Blood glucose lev- 
els were significantly decreased below initial values 2 h after ip injection 
of glucose. 
DISCUSSION 
Cu(OAc)2(Im)4 is clearly an effective hypoglycemic agent, when 
injected im or ip peritoneally into fasted rats. Doses between 20 and 60 
mg/kg were most effective and nontoxic. This hypoglycemic effect is 
dose-dependent with a duration of action of about 6 h, whereas higher 
doses of 100 mg/kg were toxic and even lethal as a result of hypo- 
glycemic shock, which induced seizures. Oral injection of copper(II) com- 
plexes was not effective in reducing blood glucose levels even with high 
doses. This could be owing to inactivation or modification of the copper 
compound by gastrointestinal secretions or inadequate absorption from 
the digestive tract. Intravenous injection of small doses caused a sharp 
increase in blood pressure, which was lethal after 1-3 rain of injection. 
The decrease in blood glucose level is consistent with the 75% reduction 
in blood insulin content, since it is well known that reduction i  blood 
glucose has a negative feedback on insulin release from the pancreas. 
This result indicates that the hypoglycemic effect of Cu(OAc)2(Im)4 is not 
owing to a direct effect on the pancreas. 
The hypoglycemic activity of copper(II) complexes varies with com- 
plex structure with Cu(OAc)2(Im)4 being the most effective and 
Cu(OAc)2(1,2dmIm)2 the least effective, whereas inorganic form of cop- 
per and imidazole(s) have only a slight hypoglycemic activity, which 
was nonsignificant. 
Copper(II) chloride has been shown to stimulate glucose incorpora- 
tion into glycogen of diaphragm uscle (9) and epididymal adipose tis- 
sue of rats (10) in vitro, and to stimulate insulin release from the perfused 
pancreas of rats (11). This may be a specific physiological role for copper 
since nickel (16), cobalt (17), manganese (18), and zinc (19) are known to 
inhibit glucose-induced insulin release in vitro. 
The fact that copper complexes were more active than inorganic op- 
per suggests that the observed pharmacological activity is owing to the 
physiochemical properties of these complexes. It is presumed that copper 
complexes facilitate absorption, distribution, and utilization of copper, 
which is essential for activation of copper-dependent zymes required 
to maintain ormal physiological processes. 
The exact mechanism underlying the effect of copper(II) acetate- 
imidazole complexes on blood glucose needs further clarification. 
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